Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18013744 | 0.89 | TDP1 (0.73) | MEN1KMT2ATDP1LMNAMAPK1 | |
| SCHEMBL11555709 | 0.89 | MEN1 (0.61) | MEN1KMT2ATDP1LMNACYP1A2 | |
| SCHEMBL11561313 | 0.89 | MEN1 (0.61) | MEN1KMT2ATDP1LMNACYP1A2 | |
| SCHEMBL11558044 | 0.85 | MEN1 (0.71) | MEN1KMT2ATDP1LMNAMAPK1 | |
| SCHEMBL11554831 | 0.85 | MEN1 (0.71) | MEN1KMT2ATDP1LMNAMAPK1 | |
| SCHEMBL991809 | 0.84 | MEN1 (0.66) | MEN1KMT2ATDP1LMNAMAPK1 | |
| SCHEMBL992355 | 0.84 | MEN1 (0.66) | MEN1KMT2ATDP1LMNAMAPK1 | |
| SCHEMBL18256284 | 0.84 | MEN1 (0.66) | MEN1KMT2ATDP1LMNAMAPK1 | |
| SCHEMBL19821665 | 0.82 | MEN1 (0.66) | MEN1KMT2ATDP1LMNAMAPK1 | |
| SCHEMBL992244 | 0.81 | MEN1 (0.61) | MEN1KMT2ATDP1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2641906-B1 | Tofa analogs useful in treating dermatological disorders or conditions | DERMIRA CANADA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-20150025069-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA CANADA INC (US) | 2015-01-22 | — | — | US | claimed |
| EP-2641906-A1 | Tofa analogs useful in treating dermatological disorders or conditions | Dermira (Canada), Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| EP-2451796-B1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA CANADA INC (US) | 2013-04-17 | — | — | EP | claimed |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2012-08-16 | — | — | US | claimed |
| EP-2451796-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Dermira (Canada), Inc. (CA) | 2012-05-16 | — | — | EP | claimed |
| WO-2011005660-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2011-01-13 | — | — | WO | claimed |
| US-20260034091-A1 | Compositions and Methods for Treating Metabolic Disorders | UNIV CALIFORNIA (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4561557-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | The Regents of the University of California (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026012-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2022005871-A1 | METHODS OF TREATING SARS-COV-2 INFECTION USING INHIBITORS OF LIPOGENESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-06 | — | — | WO | disclosed |
| US-9782382-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9782382-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2451796-B1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA CANADA INC (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2451796-B1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA CANADA INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2012-08-16 | — | — | US | disclosed |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2012-08-16 | — | — | US | disclosed |
| EP-2451796-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Dermira (Canada), Inc. (CA) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011005660-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005660-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025069-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | MEN1 4056/4885KMT2A 2716/4885TDP1 3363/4885 |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | MEN1 3929/4885KMT2A 3026/4885TDP1 3323/4885 |
| US-20260034091-A1 | Compositions and Methods for Treating Metabolic Disorders | LIPC, GPR119, PNLIP | MEN1 3713/4885KMT2A 3144/4885TDP1 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.